
    
      This is a global phase III clinical trial to evaluate efficacy,safety, immuogenicity of
      Ad5-nCoV manufactured by Cansino and Beijing Institute of Biotechnology in health adults aged
      18 years old and above.

      The study will be double-blind, placebo-controlled trial with participants randomly allocated
      1:1 to placebo and experimental vaccine cohorts.

      The immunization schedule is one doses intramuscular injections (deltoid).
    
  